On this week’s show, Staff Writer Jennifer Couzin-Frankel joins host Sarah Crespi to talk about a Science paper that combines two hot areas of research—CRISPR gene editing and immunotherapy for cancer—and tests it in patients.
Sarah also talks with Damien Finch, a Ph.D. candidate in the School of Earth Sciences at the University of Melbourne, about the Kimberly region of Australia and dating its ice age cave paintings using charcoal from nearby wasp nests.
From a CalTech news article (February 4, 2020):
The hope, Lee says, is that ultrasound will kill cancer cells in a specific way that will also engage the immune system and arouse it to attack any cancer cells remaining after the treatment.
A new technique could offer a targeted approach to fighting cancer: low-intensity pulses of ultrasound have been shown to selectively kill cancer cells while leaving normal cells unharmed.
Ultrasound waves—sound waves with frequencies higher than humans can hear—have been used as a cancer treatment before, albeit in a broad-brush approach: high-intensity bursts of ultrasound can heat up tissue, killing cancer and normal cells in a target area. Now, scientists and engineers are exploring the use of low-intensity pulsed ultrasound (LIPUS) in an effort to create a more selective treatment.
A study describing the effectiveness of the new approach in cell models was published in Applied Physics Letters on January 7. The researchers behind the work caution that it is still preliminary—it still has not been tested in a live animal let alone in a human, and there remain several key challenges to address—but the results so far are promising.
Cardiovascular disease remains the leading cause of death worldwide among middle-aged adults. However, deaths from cancer are catching up in high-income countries according to a study recently published in the medical journal The Lancet. Researchers calculated that cancer kills about twice as many people as cardiovascular disease in more developed countries. Globally, cancer could become the leading cause of death in just a few decades, the study said.
From a JAMA Network Open online release (Jan 31, 2020):
Steep incidence increases between 49 and 50 years of age are consistent with previously undetected colorectal cancers diagnosed via screening uptake at 50 years. These cancers are not reflected in observed rates of colorectal cancer in the SEER registries among individuals younger than 50 years. Hence, using observed incidence rates from 45 to 49 years of age alone to assess potential outcomes of earlier screening may underestimate cancer prevention benefits.
Early-onset colorectal cancer (EOCRC) incidence rates are increasing, and controversy exists regarding whether average-risk screening should begin at 45 or 50 years of age.1 In 2018, the American Cancer Society recommended that average-risk screening start at 45 years of age.2 Others recommend screening at 50 years of age, although the US Multi-Society Task Force on Colorectal Cancer recommends screening African American individuals at age 45 years of age owing to higher incidence, mortality, and earlier-onset disease.3–6 The American Cancer Society decision incorporated modeling studies that used updated incidence and mortality data encompassing time periods of increasing EOCRC incidence rates; modeling compared life-years gained by initiating screening at 45 vs 50 years.
It’s called gamma knife surgery, but there’s no cutting involved. It’s been used at Mayo Clinic for 30 years as an alternative to open brain surgery.
The patient’s head is held still during the procedure with a headframe, which also serves as a map for the radiation. Using 3D imaging — typically an MRI — as a guide, the gamma knife is targeted directly at the tumor. And with no hospital stay and minimal side effects, it’s a procedure that is efficient and can be lifesaving.
Though a law requiring clinical trial results reporting has been on the books for decades, many researchers have been slow to comply. Now, 2 years after the law was sharpened with higher penalties for noncompliance, investigative correspondent Charles Piller took a look at the results. He talks with host Sarah Crespi about the investigation and a surprising lack of compliance and enforcement.
Also this week, Sarah talks with Brett Finlay, a microbiologist at the University Of British Columbia, Vancouver, about an Insight in this week’s issue that aims to connect the dots between noncommunicable diseases like heart disease, diabetes, and cancer and the microbes that live in our guts. Could these diseases actually spread through our microbiomes?
Named after the late Frederic Mohs, M.D., Mohs micrographic surgery is a highly precise excision technique in which the cancer is removed in stages, one tissue layer at a time. After each removal step, the layer is examined under a microscope to determine whether cancer remains in the patient’s skin and, if present, where exactly it is located so that the surgeon can pinpoint where to remove the remaining skin cancer. This allows for the smallest scar and best cosmetic result.
This interview originally aired Jan. 4, 2020.
Boomers Daily 